Abbott’s Medical Device Growth Despite Market Challenges

Abbott Laboratories has reported a robust first half of 2025, showcasing a notable 14.8% increase in its US medical device sales compared to H1 2024. This growth marks a significant achievement in navigating market shifts and economic pressures. A key element of Abbott’s success lies in the stability of average selling prices (ASPs) across its top revenue product lines, ensuring resilience against fluctuating market conditions. 

Abbott’s performance highlights its ability to adapt within the evolving US medical device market. According to GlobalData, although some of Abbott’s high-volume products experienced ASP fluctuations, its flagship lines managed to maintain consistent pricing between 2024 and 2025. This stability allowed Abbott to sustain a strong position in the industry, correlating with changing purchasing strategies from healthcare facilities that prioritize cost-efficiency and public health needs. Notable gains were seen across Abbott’s key offerings such as MitraClip, Ensite X, and Tactiflex, helping the company achieve an 18% share of the US cardiovascular market.